Oncology biomarkers have many potential applications, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of disease progression. Tumor markers are substances that are produced by cancer or by other cells of the body in response to cancer or certain benign conditions. Most tumor markers are made by normal cells as well as by cancer cells; however, they are produced at much higher levels in cancerous conditions. These substances can be found in the blood, urine, stool, tumor tissue, or other tissues or bodily fluids of some patients with cancer.

 

MSD provides solutions to support and simplify your oncology & cancer research needs. We offer singleplex and multiplex assays to measure biomarkers such as phosphoproteins and intracellular signaling proteins, as well as biomarkers associated with angiogenesis and apoptosis.

• Human
• Mouse
• Rat
• All Species

Title	Journal	Year
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma Paolo Strati, Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng, Ryan Sun, Sherry Adkins, Swapna Johncy, Taylor Cain, Raphael E. Steiner, Sairah Ahmed, Dai Chihara, Luis E. Fayad, Swaminathan P. Iyer, Sandra Horowitz, Loretta J. Nastoupil, Ranjit Nair, Ahmed Hassan, Taher E. Daoud, Misha Hawkins, Maria A. Rodriguez, Elizabeth J. Shpall, Jeremy L. Ramdial, Partow Kebriaei, David S. Hong, Jason R. Westin, Sattva S. Neelapu, Michael R. Green	Blood Advances	2023
Prostate-Specific Antigen and Female Breast Cancer-Revisited Ziyad Khatab, Ioannis Prassas, Martin Stengelin, Eleftherios P Diamandis	The Journal of Applied Laboratory Medicine	2023
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke Fiona Chapman, Sarah Jean Pour, Roman Wieczorek, Edgar Trelles Sticken, Jessica Budde, Karin Röwer, Sandra Otte, Elizabeth Mason, Lukasz Czekala, Thomas Nahde, Grant O’Connell, Liam Simms and Matthew Stevenson	Frontiers in Toxicology	2023
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations Yijun Jia, Xuefei Li, Chao Zhao, Shengxiang Ren, Chunxia Su, Guanghui Gao, Wei Li, Fei Zhou, Jiayu Li, and Caicun Zhou	Frontiers in Oncology	2020
Plasma-Derived Inflammatory Proteins Predict Oral Squamous Cell Carcinoma Kelly Yi Ping Liu, Xian Jun David Lu, Yuqi Sarah Zhu, Nhu Le, Hugh Kim, and Catherine F. Poh	Frontiers in Oncology	2018
View All